Interestingly, characterisation of residual tumours showed some changes in HR and HER2 status, T-stage and Ki67 in HER2+ tumours, supporting the importance of accurate assessment of these biomarkers in residual disease. The gene discussed is ERBB2; the disease is neoplasm.